According to IMARC Group, the global Connected Drug Delivery Devices Market was valued at USD 1,332.0 Million in 2025 and is projected to reach USD 8,520.4 Million by 2034, expanding at a remarkable CAGR of 22.21% during 2026–2034. This extraordinary growth reflects the convergence of rising chronic disease prevalence, technological innovation, expanding telemedicine adoption, and an intensified global focus on improving patient outcomes through digital health solutions.
Connected Drug Delivery Devices Market Size & Overview
The connected drug delivery devices market size underscores a sector positioned at the crossroads of medical device innovation, digital connectivity, and personalized healthcare. Connected drug delivery devices combine traditional drug administration mechanisms — inhalers, injectors, infusion pumps — with cutting-edge IoT sensors and data transmission capabilities, enabling real-time monitoring of dosage, technique, and adherence.
These devices serve a dual purpose: ensuring patients receive the correct medication at the right time, while simultaneously transmitting data to healthcare providers, caregivers, and digital health platforms. Key device categories include:
- Connected Sensors: Connected Inhaler Sensors and Connectable Injection Sensors
- Integrated Connected Devices: Connected Inhalation Devices and Connected Injection Devices
These solutions are widely deployed for managing asthma, COPD, diabetes, cardiovascular diseases, and other chronic conditions — forming the backbone of next-generation digital therapeutics.
Global Market Overview & Connected Drug Delivery Devices Market Analysis
Below are the key statistics from IMARC Group's comprehensive Connected Drug Delivery Devices Market Analysis:
| Report Attribute | Key Statistics |
| Base Year | 2025 |
| Historical Period | 2020–2025 |
| Forecast Period | 2026–2034 |
| Market Size in 2025 | USD 1,332.0 Million |
| Market Forecast in 2034 | USD 8,520.4 Million |
| Market Growth Rate (2026–2034) | 22.21% CAGR |
| Largest Region | North America (41.2% share in 2025) |
Request for a Sample Report for Detailed Market Insights Evaluation: https://www.imarcgroup.com/connected-drug-delivery-devices-market/requestsample
Key Market Drivers & Trends in 2026
Several powerful forces are accelerating growth across the global connected drug delivery devices landscape:
- Rising Prevalence of Chronic Diseases
Chronic conditions — including asthma, COPD, diabetes, and cardiovascular diseases — are the primary drivers of demand. Connected drug delivery devices ensure accurate dosing, track adherence patterns, and transmit health data to providers, making them indispensable for long-term disease management. According to the WHO, the global population aged over 60 is expected to nearly double by 2050, reaching approximately 2.1 billion — significantly expanding the patient pool requiring connected medication solutions.
- Technological Advancements in IoT and Sensor Integration
Rapid innovation in sensor technology, wireless communication (Bluetooth, NFC), and seamless integration with mobile applications is dramatically enhancing the functionality of connected drug delivery devices. Bluetooth leads the technology segment with a 61.8% market share in 2025, driven by its low power consumption, broad device compatibility, and reliable real-time data transmission capabilities.
- Thriving Telemedicine and Digital Health Sector
The global telemedicine market reached USD 74.7 Billion in 2023, and its continued expansion is a key catalyst for connected drug delivery device adoption. These devices integrate with telehealth platforms, enabling remote monitoring of medication adherence, treatment response, and patient health status — bridging the gap between patients and caregivers across geographies.
- Growing Aging Population and Need for Remote Monitoring
An aging global population is increasingly susceptible to multiple chronic conditions requiring precise, consistent medication delivery. Connected devices simplify complex regimens through automated reminders, dosage tracking, and real-time alerts to healthcare providers, supporting aging-in-place and reducing costly hospitalizations.
- Rising Burden of COPD and Respiratory Diseases
Nearly 90% of COPD deaths in patients under 70 occur in low- and middle-income countries, per WHO data. Connected drug delivery devices address this challenge by monitoring inhalation technique, ensuring optimal bronchodilator and corticosteroid delivery, and enabling early detection of disease exacerbations through remote monitoring.
- COVID-19 Pandemic as a Catalyst for Home-Based Care
The COVID-19 pandemic accelerated demand for self-monitoring and home-based medication management solutions. Reduced in-person healthcare visits created urgent demand for connected devices enabling remote management, bolstered by expanded reimbursement policies for telehealth and digital health innovations.
Key Market Segmentation
By Product
- Integrated Connected Devices – Largest Segment (56.8% share in 2025)
Integrated connected devices — spanning connected inhalation devices and connected injection devices — dominate the market due to their comprehensive approach to combining drug delivery with advanced monitoring capabilities. These devices provide real-time tracking of medication usage, technique, and dosage, offering actionable insights for both patients and healthcare providers.
- Connected Sensors (Connected Inhaler Sensors, Connectable Injection Sensors)
By End User
- Hospitals and Healthcare Providers – Largest Segment (59.3% share in 2025)
Hospitals lead the end-user segment due to their critical need for efficient patient care, improved medication adherence, and better treatment outcomes. Connected drug delivery systems allow healthcare providers to streamline medication management, monitor patient progress, and enable more personalized treatments — while real-time device data enhances clinical decision-making.
- Homecare
By Technology
- Bluetooth – Largest Segment (61.8% share in 2025)
Bluetooth dominates the technology segment due to its low power consumption, widespread compatibility with smartphones and healthcare platforms, and reliable wireless data transmission. These attributes make Bluetooth the natural choice for connecting drug delivery devices with mobile applications and remote monitoring systems.
- NFC
- Other Technologies
Regional Market Analysis
| Region | Key Highlights |
| North America – Largest (41.2%) | United States & Canada; high healthcare expenditure (USD 4.5 Trillion in 2022), robust FDA regulatory framework, expanding reimbursement for connected devices, strong pharmaceutical and medical device R&D investment |
| Europe | Germany, France, UK, Italy, Spain, Russia; rapidly aging population (1 in 5 Europeans aged 65+, projected 30% by 2050), growing demand for remote monitoring, supportive digital health policies |
| Asia Pacific | China, Japan, India, South Korea, Australia, Indonesia; Indian digital healthcare expected to grow from USD 2.7B (2022) to USD 37B by 2030, rising telemedicine adoption |
| Latin America | Brazil, Mexico; significant COPD burden driving device adoption (1.1M+ COPD-related deaths in Brazil 2000–2019), growing focus on chronic disease management |
| Middle East & Africa | UAE, Saudi Arabia, South Africa; rapid healthcare facility expansion (4,482+ private medical facilities in Dubai), healthcare modernization programs fueling connected device adoption |
Connect for Detailed Segmentation Analysis – Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=3738&flag=C
Leading Players in the Connected Drug Delivery Devices Industry
The global connected drug delivery devices market features a competitive mix of established medical device manufacturers, pharmaceutical companies, and specialized digital health innovators. Key companies covered in the IMARC Group report include:
- Adherium Ltd.
- BioCorp Production
- Cohero Health Inc. (AptarGroup Inc.)
- Elcam Medical ACS. Ltd
- Findair Sp. z o. o.
- Merck KGaA
- Phillips Medisize (Molex LLC)
- Propeller Health (ResMed Inc.)
- Teva Pharmaceutical Industries Ltd.
- West Pharmaceutical Services Inc.
The report includes comprehensive competitive analysis covering market structure, player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant.
Latest Industry Developments
October 2024 – Modivcare Inc. & Adherium
Modivcare Inc., a leader in tech-driven healthcare services, partnered with Tenovi to introduce Adherium's Hailie Smart inhalers through its subsidiaries, VRI and Higi Care. This collaboration aims to improve care for patients with chronic respiratory conditions by leveraging connected drug delivery technology.
September 2024 – SHL Medical
SHL Medical, a leader in self-injection solutions, launched the Elexy device — an electromechanical drug delivery system featuring cellular and Bluetooth connectivity. Elexy enhances digital therapeutics by enabling comprehensive data collection on drug usage, device performance, and container details.
June 2024 – Aptar Digital Health & SHL Medical
Aptar Digital Health teamed up with SHL Medical to enhance connected drug delivery systems, combining Aptar's software expertise with SHL's autoinjectors and pen injectors to offer better solutions for managing injectable therapies.
May 2024 – Adherium Limited
Adherium Limited announced that AstraZeneca selected its Hailie® Smartinhaler® platform for a clinical trial, with a contract valued at USD 1.1 Million over three years — underscoring growing pharmaceutical industry confidence in connected inhaler technology.
About Us
IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Healthcare, Energy, Food & Beverages, Chemicals and Materials, and more.
Contact Us
IMARC Group
United States: +1-201-971-6302
India: +91-120-433-0800
United Kingdom: +44-753-714-6104